Cost Matters

References

1. Guirgis HM (2022) The Impact of The Immune Check Point on Cost in Lung Cancer: Duration of use. ESMED 10(6).
2. Helmy MG (2023) Target Therapy vs the Immune Check Point Inhibitors in Lung Cancer: Costs and Caps Platform 11(2).
3. Herbst RS, Baas P, Kim DW, Felip E, Perez GJL, et al. (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-postive, advanced non-small-cell lung cancer (KEYNOTE -010): A randomised controlled trial. Lancet 387(10027): 1540-1550.
4. Garon EB, Rizvi NA, Hui R, Leighl N, Ani SB, et al. (2015) Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med 372: 2018-2028.
5. Reck M, Rodriguez AD, Robinson AG, Hui R, Csoszi T, et al. (2016) Pembrolizumab versus chemotherapy for PD- L1-positive nonsmall-cell lung cancer. N Engl J Med 375: 823-1833.
6. Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, et al. (2020) Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC. N Engl J Med 383: 1328-1339.
7. Sezer A, Kilickap S, Gumus M, Bondarenko I, Ozguroglu M, et al. (2021) Cemiplimab monotherapy for first- line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet 397(10274): 592-604.
8. Kline RK (2021) Bundled Payment Models in Oncology: Learning to Think in New Ways. JCO Oncol Pract 17(4): 169-172.
9. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, et al. (2022) Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 386: 1973-1985.
10. Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, et al. (2015) American Society of Clinical Oncology statement: A framework to assess the value of cancer treatment options. J Clin Oncol 33(23): 2563-2577.
11. Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, et al. (2015) A standardized, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies. The European Society for Medical Oncology: magnitude of clinical benefit scale (ESM-MCBS): Ann Oncol 28(11): 2901- 2905.
12. Siegel JE, Weinstein MC, Russell LB, Gold MR, Kamlet MS (1996) Panel on cost-effectiveness in health and medicine. Recommendations for reporting cost effectiveness analyses. JAMA. 276(15): 1253-1258.
13. Li M, Liao K, Pan IW, Shih YT (2022) Growing Financial burden from high cost targeted oral anticancer medicines among Medicare beneficiaries with cancer. JCO oncology practice 18(11): 1739-1749.